Anzeige
Mehr »
Login
Freitag, 21.02.2025 Börsentäglich über 12.000 News von 688 internationalen Medien
Neues Allzeithoch: Sensationelle Goldfunde! - könnte das der nächste Multi-Bagger sein?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A143G8 | ISIN: FR0013018124 | Ticker-Symbol: NXOA
Stuttgart
21.02.25
14:53 Uhr
0,285 Euro
+0,004
+1,42 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
NICOX SA Chart 1 Jahr
5-Tage-Chart
NICOX SA 5-Tage-Chart
RealtimeGeldBriefZeit
0,3100,31316:24

Aktuelle News zur NICOX Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
28.01.NICOX SA: Nicox Announces Scientific Presentation and Conference Attendance in H1 2025252Press Release Nicox Announces Scientific Presentation and Conference Attendance in H1 2025January 28, 2025 - release at 7:30 am CETSophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124...
► Artikel lesen
21.01.NICOX SA: Nicox Provides Business Update and Fourth Quarter 2024 Financial Highlights317Press Release Nicox Provides Business Update and Fourth Quarter 2024 Financial Highlights Last patient recruited in the NCX 470 (bimatoprost grenod) Phase 3 Denali clinical trial with topline...
► Artikel lesen
04.12.24NICOX SA: Nicox Announces First Commercial Sale of ZERVIATE in China by Partner Ocumension, Creating a New Recurrent Revenue Stream493Press Release Nicox Announces First Commercial Sale of ZERVIATE in China by Partner Ocumension, Creating a New Recurrent Revenue Stream First commercialized product from the Nicox-Ocumension...
► Artikel lesen
02.12.24NICOX SA: Nicox's Denali Phase 3 Trial of NCX 470 Fully Enrolled in China Earlier than Expected358Press ReleaseNicox's Denali Phase 3 Trial of NCX 470 Fully Enrolled in China Earlier than Expected Confirms topline results expected to be reported Q3 2025 NCX 470 demonstrated robust...
► Artikel lesen
19.11.24NICOX SA: Nicox Announces Publication of the Adaptive Design Period of the NCX 470 Mont Blanc Phase 3 Trial378Press Release Nicox Announces Publication of the Adaptive Design Period of the NCX 470 Mont Blanc Phase 3 Trial An adaptive design is a useful clinical trial design tool which allowed identification...
► Artikel lesen
17.10.24Nicox reports 1H results4
NICOX Aktie jetzt für 0€ handeln
17.10.24NICOX SA: Nicox Provides Third Quarter 2024 update and First Half 2024 Financial Results315Press Release Nicox Provides Third Quarter 2024 update and First Half 2024 Financial Results Topline results from the NCX 470 (bimatoprost grenod) Phase 3 Denali clinical trial expected in Q3...
► Artikel lesen
14.10.24NICOX SA: Nicox and Soleus Sign $16.5 million Royalty and Equity Financing314Press Release Nicox and Soleus Sign $16.5 million Royalty and Equity Financing Gross proceeds of $15 million (€13.7 million) for the sale of Nicox's net share of the VYZULTA royalty to SoleusSoleus...
► Artikel lesen
23.09.24NICOX SA: Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement469Press Release Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement Option entitles Glaukos to exclusive global license agreements on pre-agreed terms including...
► Artikel lesen
18.09.24NICOX SA: Nicox Announces Approval of ZERVIATE in China367Press Release Nicox Announces Approval of ZERVIATE in China Nicox's partner, Ocumension Therapeutics, has received approval for ZERVIATE® for ocular itching in China ZERVIATE® launch in China...
► Artikel lesen
04.09.24NICOX SA: Nicox Appoints Christine Placet to Board of Directors; Michele Garufi steps down from Board495Press Release Nicox Appoints Christine Placet to Board of Directors; Michele Garufi steps down from Board Christine Placet is CFO of Theranexus, and was formerly CEO of Horama and TrophosMichele...
► Artikel lesen
25.07.24NICOX SA: Nicox Announces Recruitment of Last Patient in U.S. in Denali Phase 3 Trial of NCX 470308Press Release Nicox Announces Recruitment of Last Patient in U.S. in Denali Phase 3 Trial of NCX 470 Recruitment continues in China, on track for topline results in H2 2025 NCX 470 demonstrated...
► Artikel lesen
19.07.24NICOX SA: Nicox announces attendance at upcoming conferences311Press Release Nicox announces attendance at upcoming conferencesJuly 19th, 2024 - release at 7:30 am CETSophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international...
► Artikel lesen
18.07.24NICOX SA: Nicox Provides Second Quarter 2024 Update409Press Release Nicox Provides Second Quarter 2024 Update Nicox Group revenue of €1.6 million (net revenue1 €1.0 million) for second quarter 2024Nicox Group cash of €7.8 million on 30 June 2024...
► Artikel lesen
16.07.24NICOX SA: Nicox appoints experienced biotech leader Damian Marron as Chair of the Board and Marc Le Bozec as Director321Press Release Nicox appoints experienced biotech leader Damian Marron as Chair of the Board and Marc Le Bozec as Director Damian Marron is an experienced healthcare executive, non-executive Director/Chair...
► Artikel lesen
27.06.24NICOX SA: Nicox: 2024 Ordinary Shareholder Meeting316Press Release Nicox: 2024 Ordinary Shareholder MeetingJune 27, 2024 - release at 17:30 CET Sophia Antipolis, FranceNicox SA (Euronext Paris: FR0013018124, ALCOX), an international ophthalmology company...
► Artikel lesen
03.06.24XFRA CAPITAL ADJUSTMENT INFORMATION - 03.06.2024604Das Instrument 6AH KYG063181021 AUSNUTRIA DAIRY HD-,10 EQUITY wird cum Kapitalmassnahme gehandelt am 03.06.2024 und ex Kapitalmassnahme am 04.06.2024 The instrument 6AH KYG063181021 AUSNUTRIA DAIRY...
► Artikel lesen
24.05.24NICOX SA: Nicox: 2024 Ordinary Shareholder Meeting to be held on June 28th, 2024321Press Release Nicox: 2024 Ordinary Shareholder Meeting to be held on June 28th, 2024May 24, 2024 - release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX)...
► Artikel lesen
10.05.24XFRA CAPITAL ADJUSTMENT INFORMATION - 10.05.2024395Das Instrument O06 SE0002158568 EASTNINE AB EQUITY wird cum Kapitalmassnahme gehandelt am 10.05.2024 und ex Kapitalmassnahme am 13.05.2024 The instrument O06 SE0002158568 EASTNINE AB EQUITY is traded...
► Artikel lesen
06.05.24NICOX SA: Nicox's Ordinary and Extraordinary Shareholders' Meeting on May 6, 2024369Press Release Nicox's Ordinary and Extraordinary Shareholders' Meeting on May 6, 2024 Shareholders adopted all resolutions proposed by the Board of Directors at the Ordinary and Extraordinary...
► Artikel lesen
Seite:  Weiter >>
29 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1